The global infectious disease therapeutics market size is predicted to growing at a CAGR of 7.96% from 2021 to 2026. The market is forecasted to grow USD 166.46 billion by 2026 from USD 113.5 billion in 2021.
Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, parasites. These diseases can be transmitted from one another by direct contact or indirect contact, and Anti-infective drugs are used to inhibit the disease's growth. These drugs can act through the host defense system and can directly target the causative agent. Globally, significant problems on public health are posed by infectious diseases such as malaria, HIV, tuberculosis, influenza, hepatitis A and hepatitis C. These diseases are the primary cause of deaths in the world.
MARKET DRIVERS:
Some of the significant factors driving the growth of the infectious disease therapeutics market are increasing the occurrence of infectious diseases, the growing use of direct-acting anti-viral, increasing healthcare expenditure, and increasing the geriatric population, growing healthcare awareness, increasing government funding’s in developing countries. The primary factor restraining the market's growth is generic erosion, Patent expiration of infectious disease drugs.
The growing prevalence for the acceptance of advanced technological developments in healthcare centers is ascribed to bolster the market's demand. Increasing disposable income in developed and developing countries is also to outshine the growth rate of this market. A rise in the awareness over various diseases and knowing benefits in early diagnosis among individuals is lucrative to surge growth opportunities for the infectious disease therapeutics market. Also, the introduction of reimbursement schemes in favor of ordinary people is lavishing this market's demand.
MARKET RESTRAINTS:
However, the lack of skilled persons in manufacturing effective drugs is slightly hindering the market's growth. Rapid changes in economic strategies may also impact negatively on the development of the infectious therapeutics market. The challenging thing for the market developers is the availability of alternative methods at a lower cost. Less knowledge over generic erosion is also one of the factors inhibiting the demand of the market.
Impact of COVID-19 on the global infectious disease therapeutics market:
The outbreak of COVID 19 is unexpectedly affecting many countries. The virus is affecting huge people, especially patients with infectious diseases. The rising cases of the COVID-19 everywhere escalate the growth rate of the infectious disease therapeutics market. Many key players are in the race to find out a vaccine or drugs for the novel coronavirus. Meanwhile, infectious disease therapeutics is the only way to control the spread of infectious diseases. The demand of the market is expected to continue in the same position in the coming years.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Mode of Treatment, Target Organism, Infection Type, Distribution Channels & Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals and Mitsubishi Tanabe Pharma |
This research report on the global infectious disease therapeutics market has been segmented and sub-segmented based on the mode of treatment, target organism, infection type, distribution channels & region.
Infectious Disease Therapeutics Market - By Mode of Treatment:
Based on the mode of treatment, the Drug mode of treatment is predicted to register the largest share in the global market during the forecast period. Rising the elderly population across the world is an attribute leveling up the growth rate of this segment. Also, increasing spending on healthcare, especially in well-developed countries, is surging market demand.
Infectious Disease Therapeutics Market - By Target Organism:
Based on the target organism, the Antibacterial segment was playing a leading role in the recent past and is estimated to be continuing its dominance during the forecast period. A rise in the number of people suffering from various infectious diseases like HIV, tuberculosis, influenza, hepatitis A and hepatitis C increases market demand. Growing disposable income in urban areas is also a factor in expanding the growth shares of the market.
Infectious Disease Therapeutics Market – By Infection type:
Based on Infection type, Bacterial infection type is growing faster from the past few years and is also anticipated to reach the highest CAGR. The introduction of innovative products manufactured with advanced technology is boosting up the growth rate of the market.
Infectious Disease Therapeutics Market – By Distribution Channels:
Based on distribution channels, the hospital segment is forecasted to lead among all during the forecast period. A rise in hospitals' construction with the latest equipment is fuelling the growth rate of the infectious disease therapeutics market.
Infectious Disease Therapeutics Market – By Region:
Geographically, North American market is expected to account for the highest share in the global infectious disease therapeutics market, followed by Asia-Pacific and Europe owing to the rising incidence of infectious diseases and the increasing aging population. Asia-Pacific is projected to account for the highest CAGR over the forecast period due to increasing government funding in emerging countries such as India and China.
North America is forecasted to dominate the global infectious disease therapeutics market with the highest share of 38.6% of the total share. The market in this region is accredited because of the regular increase of infectious diseases, growing outgoings for healthcare, and mounting alertness in healthcare. Escalating funds and investments from the government, especially in developed nations of the region, boosts market growth. The United States is leading the market due to manufacturers and a growing number of clinical trials in developing novel drugs to treat infectious diseases. Canada is observed to have rapid growth in the region.
Europe is behind North America and is the second largest in the infectious disease therapeutics market due to the increased inpatient count, the vast amount spent on healthcare, and support from the European government towards research and development activities for the drug development used for treating infectious diseases in patients. Nearly 32,000 predicted mortalities with tuberculosis and approximately 323,000 new tuberculosis cases were recorded in Europe in 2015, as per the World Health Organization (WHO). In February 2018, more than 44,000 people lost their lives suffering from lung diseases associated with seasonal influenza in Europe.
The infectious disease therapeutics market of Asia-Pacific is believed to have the quickest growth. Increasing patient population, acceptable government policies such as a decrease in excise and customs duty later exceptions in service tax, particularly in India, is accelerating the region's market growth. Rapid ongoing enhancements in countries like India and China. For instance, researchers from the Indian Institute of Science have invented a novel drug combination to treat tuberculosis better.
Infectious disease therapeutic of Latin America is believed to have constant and fixed growth. The market in this region is driven because of the escalating elder people population, increasing healthcare cognizance. Brazil is dominating the market in the area.
Middle East & Africa hold a minimal share in the infectious disease therapeutics market. The vast financial outgoings and existence of improved economies like Kuwait, Saudi Arabia, and Qatar. In Africa, the majority of people are infected with malaria. Approximately 90% of the deaths occurred because of malaria in Africa, as per World Health Organization (WHO) in 2015. In Africa, the market is flourishing due to different measures centering on disease stopping are being attempted in the region. For example, in June, Pfizer has combined with the UAE government in escalating the awareness regarding the infectious diseases is impelling the growth rate of the market in this region.
KEY MARKET PLAYERS:
Some of the promising companies leading the global infectious disease therapeutics market profiled in the report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals and Mitsubishi Tanabe Pharma.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Mode of Treatment
5.1.1 Introduction
5.1.2 Drugs
5.1.2.1 Oral Administration
5.1.2.2 Topical
5.1.2.3 Injections
5.1.2.4 Others
5.1.3 Vaccines
5.1.4 Y-o-Y Growth Analysis, By Mode of treatment
5.1.5 Market Attractiveness Analysis, By Mode of treatment
5.1.6 Market Share Analysis, By Mode of treatment
5.2 Target Organism
5.2.1 Introduction
5.2.2 Antibacterial
5.2.3 Antifungal
5.2.4 Antiviral
5.2.5 Antiparasite
5.2.6 others
5.2.7 Y-o-Y Growth Analysis, By Target Organism
5.2.8 Market Attractiveness Analysis, By Target Organism
5.2.9 Market Share Analysis, By Target Organism
5.3 Infection type
5.3.1 Introduction
5.3.2 Bacterial
5.3.3 Viral
5.3.4 Fungal
5.3.5 parasitic
5.3.6 others
5.3.7 Y-o-Y Growth Analysis, By Infection type
5.3.8 Market Attractiveness Analysis, By Infection type
5.3.9 Market Share Analysis, By Infection Type
5.4 Distribution Channels
5.4.1 Hospitals
5.4.2 Clinics
5.4.3 Others
5.4.4 Y-o-Y Growth Analysis, By Distribution Channels
5.4.5 Market Attractiveness Analysis, By Distribution Channels
5.4.6 Market Share Analysis, By Distribution Channels
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Mode of Treatment
6.1.3.3 By Target organism
6.1.3.4 By Infection Type
6.1.3.5 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Mode of Treatment
6.1.4.3 By Target organism
6.1.4.4 By Infection Type
6.1.4.5 By Distribution Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Mode of Treatment
6.1.5.3 By Target organism
6.1.5.4 By Infection Type
6.1.5.5 By Distribution Channels
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 F. Hoffmann-La Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Gilead Sciences
8.3 GlaxoSmithKline
8.4 Johnson & Johnson
8.5 Merck & Co
8.6 Pfizer
8.7 Achillion Pharmaceuticals
8.8 Novartis
8.9 Abbvie
8.10 Astellas Pharma
8.11 AstraZeneca
8.12 Auritec Pharmaceuticals
8.13 Bayer
8.14 Bristol-Myers Squibb
8.15 Chimerix Pharmaceuticals
8.16 Cubist
8.17 Eli Lilly
8.18 Isis Pharmaceuticals
8.19 pSivida
8.20 Sanofi
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
